Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from MEI Pharma

Top 4 Pharma Stocks to Consider This Month

With growing medical needs globally, R&D initiatives, and rapid adoption of emerging technologies like genAI, the pharma industry is well-poised to experience robust expansion. Thus, investors could consider buying top pharma stocks MEI Pharma (MEIP), Hypera (HYPMY), Aurinia Pharmaceuticals (AUPH), and Bayer (BAYRY) this month. Read on.

Looking Into MEI Pharma's Return On Capital Employed

Looking Into MEI Pharma's Return On Capital Employed

According to Benzinga Pro data, during Q3, MEI Pharma (NASDAQ:MEIP) posted sales of $9.69 million. Earnings were up 28.22%, but MEI Pharma still reported an overall loss of $8.72 million.

Expert Ratings For MEI Pharma

Expert Ratings For MEI Pharma

Analysts have provided the following ratings for MEI Pharma (NASDAQ:MEIP) within the last quarter:

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Analysts Cut Price Target On MEI Pharma As Stock Falls To 52-Week Low After Zandelisib Update

The FDA crushed MEI Pharma Inc's (NASDAQ: MEIP) hopes of winning accelerated approval for its PI3K inhibitor, zandelisib, on the strength of phase 2 data.

12 Health Care Stocks Moving In Friday's Intraday Session

Stocks That Hit 52-Week Lows On Friday

On Friday, 166 companies set new 52-week lows.

Benzinga's Top Ratings Upgrades, Downgrades For March 25, 2022

Upgrades For Aris Water Solutions Inc (NYSE:ARIS), Capital One upgraded the previous rating of Equal-Weight to Overweight. The stock has a 52-week-high of $19.16 and a 52-week-low of $10.06. At the end of the last trading period, Aris Water Solutions closed at $18.55.

inkl

Read news from The Economist, FT, and more,
with one subscription

The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO

The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO

Here's a roundup of top developments in the biotech space over the last 24 hours.

10 Biggest Price Target Changes For Friday

10 Biggest Price Target Changes For Friday

Jefferies cut the price target on MEI Pharma, Inc. (NASDAQ: MEIP) from $4 to $1. MEI Pharma shares fell 44.2% to $1.01 in pre-market trading.

12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Thursday's After-Market Session

Why MEI Pharma Stock Is Plummeting After Hours

Why MEI Pharma Stock Is Plummeting After Hours

MEI Pharma Inc (NASDAQ: MEIP) shares are plunging in Thursday's after-hours session after the company provided an investor update following a recent meeting with the U.S. Food and Drug Administration.

MEI Pharma's Return On Capital Employed Insights

MEI Pharma's Return On Capital Employed Insights

According to data from Benzinga Pro, during Q2, MEI Pharma's (NASDAQ:MEIP) reported sales totaled $18.22 million. Despite a 51.46% increase in earnings, the company posted a loss of $5.77 million.

Recap: MEI Pharma Q2 Earnings

Recap: MEI Pharma Q2 Earnings

MEI Pharma (NASDAQ:MEIP) reported its Q2 earnings results on Thursday, February 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings MEI Pharma beat estimated earnings by 55.0%, reporting an EPS of $-0.09 versus an estimate of $-0.2.

Organisations

Intuitive Surgical

Medical Pharmaceuticals

Truist Securities

BristolMyers Squibb

Prudential Financial

Stanley Black Decker

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

244,415 stories

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play